Systemic CD4 immunity: a powerful clinical biomarker for PD-L1/PD-1 immunotherapy
| dc.contributor.author | Zuazo Ibarra, Miren | |
| dc.contributor.author | Arasanz Esteban, Hugo | |
| dc.contributor.author | Bocanegra Gondán, Ana Isabel | |
| dc.contributor.author | Chocarro de Erauso, Luisa | |
| dc.contributor.author | Vera García, Ruth | |
| dc.contributor.department | Ciencias de la Salud | es_ES |
| dc.contributor.department | Osasun Zientziak | eu |
| dc.contributor.funder | Gobierno de Navarra / Nafarroako Gobernua, BMED 050-2019 | es |
| dc.date.accessioned | 2021-02-04T12:24:45Z | |
| dc.date.available | 2021-02-04T12:24:45Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | The search for non-invasive systemic biomarkers of response to PD-L1/PD-1 blockade immunotherapy is currently a priority in oncoimmunology. In contrast to classical tumor biomarkers, the identification of clinically useful immunological biomarkers is certainly a challenge, as anti-cancer immune responses depend on the coordinated action of many cell types. Studies on the dynamics of systemic CD8 T-cell populations have provided indications that such biomarkers may have a place in clinical practice. However, the power of CD8 T-cell subsets to discriminate clinical responses in immunotherapy has so far proven to be limited. The systemic evaluation of CD8 T-cell regulators such as myeloid cells and CD4 T cells may provide the solution. Here we discuss the value of systemic quantification of CD4 T-cell subsets for patient selection in light of the results obtained by Prof. Kagamu′s and our team. Our studies have independently demonstrated that the evaluation of the pre-treatment status of systemic CD4 immunity is a critical factor for the clinical outcome of PD-L1/PD-1 blockade therapy with robust predictive capacities. | en |
| dc.description.sponsorship | This work was funded by the Spanish Association against Cancer (AECC, PROYE16001ESCO), Instituto de Salud Carlos III (ISCIII, FIS. PI17/02119), Biomedicine Project grant from the Department of Health of the Government of Navarre (BMED 050-2019), JSPS KAKENHI grant number 17H04184, and the Japan Agency for Medical Research and Development (grant nos. 19ae0101074h0001). | en |
| dc.format.extent | 3 p. | |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.doi | 10.15252/emmm.202012706 | |
| dc.identifier.issn | 1757-4684 (Electronic) | |
| dc.identifier.uri | https://academica-e.unavarra.es/handle/2454/39145 | |
| dc.language.iso | eng | en |
| dc.publisher | EMBO Press | en |
| dc.relation.ispartof | EMBO Molecular Medicine, 2020, 12(9):e12706 | en |
| dc.relation.publisherversion | https://doi.org/10.15252/emmm.202012706 | |
| dc.rights | © 2020 The Authors. Published under the terms of the CC BY 4.0 license | en |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Biomakers | en |
| dc.subject | Immunity | en |
| dc.subject | Cancer | en |
| dc.title | Systemic CD4 immunity: a powerful clinical biomarker for PD-L1/PD-1 immunotherapy | en |
| dc.type | info:eu-repo/semantics/article | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 193d800d-c38c-4627-b9d8-d29435d8214c | |
| relation.isAuthorOfPublication | fe5c362e-3c0c-4edb-aa2e-0de27c815ad2 | |
| relation.isAuthorOfPublication.latestForDiscovery | 193d800d-c38c-4627-b9d8-d29435d8214c |